INFORM2 exploratory multinational phase I/II combination study of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies: INFORM2 NivEnt.

Cornelis M. van Tilburg,Ruth Witt,Kristian W. Pajtler,Plass Christoph,Isabel Poschke,Michael Platten,Inga Harting,Oliver Sedlaczek,Angelika Freitag,David Meyrath,Lenka A. Taylor,Gnana Prakash Balasubramanian,Natalie Jäger,Elke Pfaff,Barbara C. Worst,Till Milde,Stefan M. Pfister,David T. W. Jones,Annette Kopp-Schneider,Olaf Witt

INFORM2 exploratory multinational phase I/II combination study of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies: INFORM2 NivEnt.

2019

TPS10065Background: Immune checkpoint inhibition in children has shown limited success rates until now. This is most likely due to the fact that the vast majority of pediatric cancers are so-called...

Keywords:

Refractory
Nivolumab
Physical therapy
Oncology
Entinostat
Medicine
Internal medicine
Immune checkpoint
phase i ii

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations